Contact Us: 1-518-583-0095 
We’re Hiring… Join Our Team!
Dr. Thomas Flaig of the University of Colorado and Director of the Academic Urology Research Investigators Consortium (AURIC) discusses recent developments in bladder cancer treatment, including immune checkpoint inhibitors.
Continue readingDr. Thomas Flaig of the University of Colorado and Director of the Academic Urology Research Investigators Consortium (AURIC) discusses how antibody-drug conjugates are used in the treatment of advanced urothelial cancer.
Continue reading
Learn more about D. Ross Camidge, MD, PhD, University of Colorado, Director of the Academic Thoracic Oncology Medical Investigators’ Consortium (ATOMIC), who was honored by a colleague for the 2023 Healio Honors in Medical Oncology.
Continue reading
Dr. Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab.
Continue reading
Dr. Camidge received the organization’s Daniel C. Ihde Lectureship Award for Medical Oncology.
Continue reading
Dr. Peter Kabos, MD, Associate Professor, Division of Medical Oncology and Dr. D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology were recently honored by the University of Colorado’s Division of Medical Oncology.
Continue readingATOMIC (Academic Thoracic Oncology Medical Investigators Consortium), met at the IASLC 2023 Targeted Therapies of Lung Cancer symposium in February in Santa Monica.
Continue readingAGICC (Academic GI Cancer Consortium) met in person for an Investigator’s Meeting during the recent GI-ASCO 2023 Symposium in San Francisco. This coming year the AGICC group will continue to explore GI oncology trials in partnership with pharmaceutical companies.
Continue readingThe Academic Urology Research Investigators Consortium met for an initial Investigator’s Meeting during the recent GU-ASCO 2023 in San Francisco to explore new studies for the coming year. The group’s primary focus is to partner with pharmaceutical companies looking to explore novel genitourinary oncology trials.
Continue reading
AURIC Director Thomas Flaig, MD, of the University of Colorado Anschutz Medical Campus in Aurora, Colorado, provides an overview of the management of toxicities with novel systemic therapies in patients with urothelial carcinoma (UC), highlighting the use of antibody-drug conjugates in advanced disease.
Continue reading